MESO — Mesoblast Limited

Is MESO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of August 19, 2026

Mesoblast Limited (MESO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $16.67. The rating moved from Overbought to Neutral on August 18, 2026.

AI analysis

Mesoblast operates a differentiated allogeneic cell-therapy platform with several clinical-stage programs and potential partnership value. Sector-level strength in biologics and CRO/CDMO demand provides a constructive backdrop, and the stock may be supported by modest risk-on flows in equities. However, the company currently lacks clear near-term revenue visibility and remains exposed to clinical, regulatory, manufacturing and financing risks that make the path to commercialization uncertain. Near-term price movement will likely be driven by clinical readouts, partnership/licensing news and any financing actions; absent material positive catalysts, expect muted directional movement with episodic volatility tied to trial and corporate developments.

Key factors

  • Proprietary allogeneic cell-therapy platform with multiple clinical-stage programs offering differentiated mechanisms versus small molecules
  • Sector tailwinds for biologics, CDMO/CRO demand and expanded addressable markets supporting upstream development and potential partner interest
  • Catalyst calendar potential: clinical readouts, licensing/partnership announcements or regulatory interactions could materially re-rate shares
  • Neutral recent public disclosures (6-K) with no material negative events reported, limiting immediate downward news risk
  • Market tone is modestly risk-on with flows into growth/biologics names which can support near-term share-price stability
  • Unclear near-term revenue visibility—valuation depends heavily on future successful commercialization or partnering outcomes

Risks

  • Clinical development risk: trial failures, negative efficacy/safety outcomes or delayed readouts could sharply reduce valuation
  • Regulatory risk: complex approval pathways for cell therapies and variable global regulatory standards
  • Financing and dilution risk: ongoing cash burn and need for additional capital or milestone-based partnering could dilute existing shareholders
  • Commercialization and reimbursement risk: limited in-house commercialization experience and uncertain payer adoption for novel cell therapies
  • Manufacturing and scale-up risk: high complexity and cost of cell-therapy manufacturing could constrain supply or margins
  • Competitive risk: competing biologics, cell therapies and innovative modalities targeting similar indications
  • Macroeconomic and market-sentiment risk: biotech equities are sensitive to rates, liquidity and risk appetite shifts

See today's live rating, score and targets

Members see the live hourly rating for MESO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.